Biologically Active Small Molecules

An inhibitor of the ERAD pathway, blocking the degradation of misfolded proteins at a dose of 8 &microM associates with the p97-associated deubiquitinating complex in cells, preventing deubiquitination of substrates by ataxin-3 interferes with

An inhibitor of the ERAD pathway, blocking the degradation of misfolded proteins at a dose of 8 &microM associates with the p97-associated deubiquitinating complex in cells, preventing deubiquitination of substrates by ataxin-3 interferes with

An inhibitor of the ERAD pathway, blocking the degradation of misfolded proteins at a dose of 8 &microM associates with the p97-associated deubiquitinating complex in cells, preventing deubiquitination of substrates by ataxin-3 interferes with

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

A potent inhibitor of Eg5, both in vitro and in cells (IC₅₀s = 127 and 190 nM, respectively) blocks bipolar spindle formation and inhibits the growth of cancer cells, with an average GI50 value of 360 nM against a broad panel of tumor

A potent inhibitor of Eg5, both in vitro and in cells (IC₅₀s = 127 and 190 nM, respectively) blocks bipolar spindle formation and inhibits the growth of cancer cells, with an average GI50 value of 360 nM against a broad panel of tumor

A potent inhibitor of Eg5, both in vitro and in cells (IC₅₀s = 127 and 190 nM, respectively) blocks bipolar spindle formation and inhibits the growth of cancer cells, with an average GI50 value of 360 nM against a broad panel of tumor

Afatanib is an anticancer chemotherapeutic compound that has been approved to treat advanced lung cancers such as non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for other advanced solid tumors such as breast can

Afatanib is an anticancer chemotherapeutic compound that has been approved to treat advanced lung cancers such as non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for other advanced solid tumors such as breast can